Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.

Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM, Ahmed N.

Cancer Gene Ther. 2012 Mar;19(3):212-7. doi: 10.1038/cgt.2011.83. Epub 2011 Dec 16.

PMID:
22173710
2.

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.

Fernández L, Valentín J, Zalacain M, Leung W, Patiño-García A, Pérez-Martínez A.

Cancer Lett. 2015 Nov 1;368(1):54-63. doi: 10.1016/j.canlet.2015.07.042. Epub 2015 Aug 11.

PMID:
26276724
3.

Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.

Weibo P, Zhaoming Y.

Med Hypotheses. 2012 May;78(5):616-8. doi: 10.1016/j.mehy.2012.01.038. Epub 2012 Feb 12.

PMID:
22330890
4.

Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S.

Cancer Res. 2007 Jun 15;67(12):5957-64.

5.

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S.

J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23.

6.

[Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].

Li SP, Urban FA, Macgregor JN, Hughes DP, McDonagh KT.

Ai Zheng. 2004 Nov;23(11 Suppl):1370-5. Chinese.

PMID:
15566639
7.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S.

Mol Ther. 2009 Oct;17(10):1779-87. doi: 10.1038/mt.2009.133. Epub 2009 Jun 16.

8.

A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.

Wang LF, Zhou Y, Xu YM, Qiu XC, Zhou BG, Wang F, Long H, Chen X, Yang TT, Ma BA, Fan QY, Yang AG.

Cancer Invest. 2009 Aug;27(7):774-80. doi: 10.1080/07357900802427935.

PMID:
19488908
9.

Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.

Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z.

Gastroenterology. 2012 Nov;143(5):1375-84.e1-5. doi: 10.1053/j.gastro.2012.07.017. Epub 2012 Jul 20.

PMID:
22819865
10.

A novel recombinant immunocasp-6 fusion gene specifically and efficiently suppresses HER2-overexpressing osteosarcoma.

Zhou BG, Liu MY, Qiu XC, Xu YM, Fan QY, Yang AG, Zhang Y, Xia H.

Oncol Rep. 2013 Jan;29(1):276-82. doi: 10.3892/or.2012.2122. Epub 2012 Nov 5.

PMID:
23135254
11.

Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model.

Rainusso N, Man TK, Lau CC, Hicks J, Shen JJ, Yu A, Wang LL, Rosen JM.

Cancer Biol Ther. 2011 Aug 15;12(4):278-87. Epub 2011 Aug 15.

12.

Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.

Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.

Cancer Res. 2002 Oct 15;62(20):5785-91.

13.

Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.

Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z.

Cancer Res. 2003 May 15;63(10):2470-6.

14.

Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.

Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, Demachi-Okamura A, Uemura Y, Taguchi O, Takahashi Y, Kojima S, Kuzushima K.

J Immunother. 2012 Oct;35(8):598-606.

PMID:
22996365
15.

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.

Cancer Res. 2006 Nov 15;66(22):10995-1004.

16.

Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.

Stastny MJ, Brown CE, Ruel C, Jensen MC.

J Pediatr Hematol Oncol. 2007 Oct;29(10):669-77.

PMID:
17921847
17.

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC.

Cancer Res. 2004 Dec 15;64(24):9160-6.

19.
20.

An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.

Nabekura T, Nagasawa T, Nakauchi H, Onodera M.

Cancer Immunol Immunother. 2008 May;57(5):611-22. Epub 2007 Sep 5.

PMID:
17786440

Supplemental Content

Support Center